Measurement reproducibility in the early stages of biomarker development

被引:18
作者
Liggett, WS [1 ]
Barker, PE
Semmes, OJ
Cazares, LH
机构
[1] NIST, Stat Engn Div, Gaithersburg, MD 20899 USA
[2] NIST, Div Biotechnol, Gaithersburg, MD 20899 USA
[3] Eastern Virginia Med Sch, Ctr Biomed Prote, Norfolk, VA 23507 USA
关键词
D O I
10.1155/2004/726517
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considered in this paper. For parallel studies, a way to improve reproducibility prior to identification of protein species is necessary. One approach is use of functional principal components analysis (PCA) as the basis for assessing measurement reproducibility. Reproducibility studies involve repeated measurement of a reference material such as a human serum standard. Measurement in our example is by SELDI-TOF (surface-enhanced laser desorption and ionization time-of-flight) mass spectrometry. Reproducibility is defined in reference to a source of variation, which in our example is associated with a type of commercially available protein biochip. We obtained spectra for 8 spots on each 11 chips. Two spectra are generally more alike when obtained from the same chip rather than different chips. Thus, our experiment indicates potential improvements from reducing variation in chip manufacture and chip handling during measurement. Our analysis involves careful registration of the spectra and characterization of the spectral differences. As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker.
引用
收藏
页码:295 / 307
页数:13
相关论文
共 19 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]   APPLICATION OF CHEMOMETRIC EXPERIMENTAL-DESIGNS IN CAPILLARY ELECTROPHORESIS - A REVIEW [J].
ALTRIA, KD ;
CLARK, BJ ;
FILBEY, SD ;
KELLY, MA ;
RUDD, DR .
ELECTROPHORESIS, 1995, 16 (11) :2143-2148
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]   Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments [J].
Baggerly, KA ;
Morris, JS ;
Coombes, KR .
BIOINFORMATICS, 2004, 20 (05) :777-U710
[5]  
BARKER PE, 2003, ANN NY ACAD SCI, V983, P1
[6]  
BILLHEIMER D, 2003, 5 ANN WINT WORKSH
[7]   The impact of six sigma improvement - A glimpse into the future of statistics [J].
Hahn, GJ ;
Hill, WJ ;
Hoerl, RW ;
Zinkgraf, SA .
AMERICAN STATISTICIAN, 1999, 53 (03) :208-215
[8]  
*INT ORG STAND, 1993, INT VOC BAS GEN TERM
[9]   Ruggedness study of HPLC peptide mapping for the identity of a drug compound: A chemometrics approach [J].
Lee, KR ;
Bongers, J ;
Jones, BH ;
Burman, S .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26 (02) :123-134
[10]  
Liggett W, 2003, CHANCE, V16, P24